These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21679088)

  • 1. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
    Dienstmann R; Felip E
    Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necitumumab for non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
    Di Maio M
    Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.
    Dienstmann R; Tabernero J
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1434-41. PubMed ID: 21154125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
    Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
    Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Necitumumab for the treatment of squamous cell non-small cell lung cancer.
    Brinkmeyer JK; Moore DC
    J Oncol Pharm Pract; 2018 Jan; 24(1):37-41. PubMed ID: 27913776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW; Choy H
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
    Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
    di Noia V; D'Argento E; Pilotto S; Grizzi G; Caccese M; Iacovelli R; Tortora G; Bria E
    Expert Opin Biol Ther; 2018 Sep; 18(9):937-945. PubMed ID: 30075697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Necitumumab for the treatment of advanced non-small-cell lung cancer.
    Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
    Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
    Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
    Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies.
    Siena S; Artale S; Vanzulli A; Marrapese G; Bevilacqua L; Secondino S; Sironi O; Schiavo R; Moroni M; Pedrazzoli P
    Suppl Tumori; 2002; 1(4):S46-8. PubMed ID: 12415818
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
    Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
    Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.